EXAS Exact Sciences Corporation: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Cologuard - graphic logo of issuer EXAS

Exact Sciences maintains its resilience through the automation of cancer screening, which eliminates human error. The business valuation based on EV/EBITDA confirms this stability, with the current mark standing at 326.44. Growth is supported by breakthrough DNA tests for early disease detection and an expanding insured patient base, opening new market horizons for the company.

Cologuard - EXAS Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 04/04/2026)

EXAS (exactsciences.com): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Quotes Cologuard|EXAS - Average Forecast Price
- company stock capitalization data:
Market Value Exact Sciences Inc.|EXAS - Company Buyout Price
- book value of equity indicators:
Book Value per Share Exact Sciences|EXAS - Book Valuation of Business|Market Value to Book Value Ratio exactsciences.com|EXAS - Company Total Asset Base
- company liabilities and liquidity data:
Total Debt to Capital Exact Sciences|EXAS - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Exact Sciences Corporation|EXAS - Company Aggregate Debt|Debts to Book Capitalization Exact Sciences Inc.|EXAS - Company Long-Term Debts|Company Short-Term Debts Exact Sciences|Quick Liquidity Indicator exactsciences.com
- financial results and valuation multiples details:
EXAS - Profit After Payment of Taxes|Future Profit Exact Sciences|EXAS - Company Value to Net Income|Future Price to Earnings Exact Sciences|EXAS - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Exact Sciences Inc.|EXAS - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Exact Sciences|EXAS - Net earnings per share for the last four quarters|Quarterly EPS earnings growth exactsciences.com|EXAS - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Exact Sciences
Fundamental company valuation:Cologuard EXAS
Product sample of Exact Sciences Corp

EV/EBITDA determines the business value including debt relative to operating profit before depreciation and amortization, neutralizing the impact of taxes and financing structures. Investors utilize this multiple to identify undervaluation points and analyze the efficiency of cash flow generation. The historical EV/EBITDA multiple for Exact Sciences (EXAS) allows for tracking the impact of ESG resource optimization and waste management on overall capitalization. A decrease in this metric confirms margin growth resulting from the implementation of eco-friendly diagnostic standards.

Competitors of Exact Sciences

Agilent Tech - Enterprise Value to EBITDA Ratio|Quest Corp (DGX) - Company Value to EBITDA|ILMN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio revvity.com RVTY|BIO: EV/EBITDA Multiple|NNNN - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sterigenics|QuidelOrtho Inc. (QDEL) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple OPK|CDNA - Company Value to EBITDA|Maravai LifeSciences Holdings, Inc. - Enterprise Value to EBITDA Ratio|FLGT: Enterprise Value to Operating Income Before Depreciation|Fluidigm - EV/EBITDA Multiple|CTKB - EV/EBITDA Multiple|OSUR: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Exagen|Enterprise Value to EBITDA Ratio MDXH|LUCD (Lucid Diagnostics, Inc.) - Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio PRE (Prenetics Global)|IMDX (imdxinc.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Trinity Biotech TRIB|Total Company Value to Operating Income Before Depreciation Ratio prophaselabs.com (PRPH)|Ainos - EV/EBITDA Multiple|Co-Diagnostics Inc (CODX) - Enterprise Value to EBITDA Ratio|HSCS: EV/EBITDA Multiple|BMRA - Total Company Value to Operating Income Before Depreciation Ratio|CDIO (Cardio Diagnostics Holdings Inc.) - EV/EBITDA Multiple|Company Value to EBITDA onconetix.gcs-web.com ONCO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Virax Biolabs (VRAX)|Bluejay Diagnostics Inc - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AWH (Vermillion)|AXDX - Enterprise Value to EBITDA Ratio|CENTOGENE, N.V. - EV/EBITDA Multiple|Company Value to EBITDA Enzo Biochem, Inc.|fresh2.co (FRES) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GENE - Total Company Value to Operating Income Before Depreciation Ratio|ME (23andMe Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Psychemedics Inc PMD